Your brain on drugs: Imaging of drug-related changes in the central nervous system

Radiographics

Volumn 32, Issue 3, 2012, Pages 701-719

  Tamrazi, Benita ^a   Almast, Jeevak ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; STREET DRUG;

ARTICLE; BRAIN; BRAIN DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; HUMAN; INTOXICATION; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY;

BRAIN; BRAIN DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; OVERDOSE; PHARMACEUTICAL PREPARATIONS; STREET DRUGS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84861161033     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.323115115     Document Type: Article

References (46)

1. Borne J, Riascos R, Cuellar H, Vargas D, Rojas R. Neuroimaging in drug and substance abuse part II: opioids and solvents. Top Magn Reson Imaging 2005;16(3):239-245
2. Toossi S, Hess CP, Hills NK, Josephson SA. Neurovascular complications of cocaine use at a tertiary stroke center. J Stroke Cerebrovasc Dis 2010;19(4): 273-278.
3. Fessler RD, Esshaki CM, Stankewitz RC, Johnson RR, Diaz FG. The neurovascular complications of cocaine. Surg Neurol 1997;47(4):339-345
4. Rojas R, Riascos R, Vargas D, Cuellar H, Borne J. Neuroimaging in drug and substance abuse part I: cocaine, cannabis, and ecstasy. Top Magn Reson Imaging 2005;16(3):231-238.
5. Levine SR, Brust JCM, Futrell N, et al. Cerebrovascular complications of the use of the crack form of alkaloidal cocaine. N Engl J Med 1990;323(11): 99-704
6. Brown E, Prager J, Lee HY, Ramsey RG. CNS complications of cocaine abuse: prevalence, pathophysiology, and neuroradiology. AJR Am J Roentgenol 1992;159(1):137-147.
7. Silvestrelli G, Corea F, Micheli S, Lanari A. Clinical pharmacology and vascular risk. Open Neurol J 2010;4:64-72
8. Geibprasert S, Gallucci M, Krings T. Addictive illegal drugs: structural neuroimaging. AJNR Am J Neuroradiol 2010;31(5):803-808.
9. Koch S, Sacco RL. Cocaine-associated stroke: some new insights? Nat Clin Pract Neurol 2008;4(11):579
10. Erwin MB, Hoyle JR, Smith CH, Deliargyris EN. Cocaine and accelerated atherosclerosis: insights from intravascular ultrasound. Int J Cardiol 2004;93 (2-3):301-303.
11. Daras M, Tuchman AJ, Marks S. Central nervous system infarction related to cocaine abuse. Stroke 1991;22(10):1320-1325.
12. Sen S, Silliman SL, Braitman LE. Vascular risk factors in cocaine users with stroke. J Stroke Cerebrovasc Dis 1999;8(4):254-258.
13. Berman S, O'Neill J, Fears S, Bartzokis G, London ED. Abuse of amphetamines and structural abnormalities in the brain. Ann NY Acad Sci 2008;1141: 195-220.
14. Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur J Neurol 2000;7(6):595-606.
15. Bartlett E, Mikulis DJ. Chasing chasing the dragon with MRI: leukoencephalopathy in drug abuse. Br J Radiol 2005;78(935):997-1004.
16. Keogh CF, Andrews GT, Spacey SD, Forkheim KE, Graeb DA. Neuroimaging features of heroin inhalation toxicity: chasing the dragon. AJR Am J Roentgenol 2003;180(3):847-850.
17. Offiah C, Hall E. Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 2008; 63(2):146-152.
18. Besenski N, Rumboldt Z, Emovon O, et al. Brain MR imaging abnormalities in kidney transplant recipients. AJNR Am J Neuroradiol 2005;26(9): 2282-2289.
19. Bartynski WS, Tan HP, Boardman JF, Shapiro R, Marsh JW Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol 2008;29(5):924-930.
20. Sharma P, Eesa M, Scott JN. Toxic and acquired metabolic encephalopathies: MRI appearance. AJR Am J Roentgenol 2009;193(3):879-886
21. Lin JT, Wang SJ, Fuh JL, Hsiao LT, Lirng JF, Chen PM. Prolonged reversible vasospasm in cyclosporin A-induced encephalopathy. AJNR Am J Neuroradiol 2003;24(1):102-104.
22. Kiemeneij IM, de Leeuw FE, Ramos LMP, van Gijn J. Acute headache as a presenting symptom of tacrolimus encephalopathy. J Neurol Neurosurg Psychiatry 2003;74(8):1126-1127.
23. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010;85(5): 427-432.
24. Eichler AF, Batchelor TT, Henson JW. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neurooncol 2007;9(3):373-377.
25. Inaba H, Khan RB, Laningham FH, Crews KR, Pui CH, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008; 19(1):178-184.
26. Reddick WE, Glass JO, Helton KJ, et al. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 2005;26(5):1263-1269.
27. Hagan IG, Burney K. Radiology of recreational drug abuse. RadioGraphics 2007;27(4):919-940.
28. Sullivan EV, Pfefferbaum A. Neuroimaging of the Wernicke-Korsakoff syndrome. Alcohol Alcohol 2009;44(2):155-165.
29. Zuccoli G, Santa Cruz D, Bertolini M, et al. MR imaging findings in 56 patients with Wernicke encephalopathy: nonalcoholics may differ from alcoholics. AJNR Am J Neuroradiol 2009;30(1): 171-176.
30. Bjork JM, Grant SJ, Hommer DW Cross-sectional volumetric analysis of brain atrophy in alcohol dependence: effects of drinking history and comorbid substance use disorder. Am J Psychiatry 2003;160 (11):2038-2045.
31. Harper C. The neuropathology of alcohol-related brain damage. Alcohol Alcohol 2009;44(2):136-140.
32. Chow KM, Szeto CC. Cerebral atrophy and skull thickening due to chronic phenytoin therapy. CMAJ 2007;176(3):321-323.
33. Crooks R, Mitchell T, Thom M. Patterns of cerebellar atrophy in patients with chronic epilepsy: a quantitative neuropathological study. Epilepsy Res 2000; 41(1):63-73.
34. De Marcos FA, Ghizoni E, Kobayashi E, Li LM, Cendes F. Cerebellar volume and long-term use of phenytoin. Seizure 2003;12(5):312-315.
35. Meyerhoff DJ. Effects of alcohol and HIV infection on the central nervous system. Alcohol Res Health 2001;25(4):288-298.
36. Ansari AA. Drugs of abuse and HIV: a perspective. J Neuroimmunol 2004;147(1-2):9-12.
37. Heinrich A, Runge U, Khaw AV. Clinicoradiologic subtypes of Marchiafava-Bignami disease. J Neurol 2004;251(9):1050-1059.
38. Ruiz-Martínez J, Martinez Perez-Balsa A, Ruibal M, Urtasun M,Villanua J, Martí Massó JF. MarchiafavaBignami disease with widespread extracallosal lesions and favourable course. Neuroradiology 1999; 41(1):40-43.
39. Tuntiyatorn L, Laothamatas J. Acute MarchiafavaBignami disease with callosal, cortical, and white matter involvement. Emerg Radiol 2008;15(2): 137-140.
40. Johkura K, Naito M, NakaT. Cortical involvement in Marchiafava-Bignami disease. AJNR Am J Neuroradiol 2005;26(3):670-673.
41. Honda K, Nishimiya J, Sato H, et al. Transient splenial lesion of the corpus callosum after acute withdrawal of antiepileptic drug: a case report. Magn Reson Med Sci 2006;5(4):211-215.
42. Güven H, Comoǧlu SS. Transient lesion in the splenium of the corpus callosum due to carbamazepine. Turk Neurosurg 2008;18(3):264-270.
43. Pema PJ, Horak HA, Wyatt RH. Myelopathy caused by nitrous oxide toxicity. AJNR Am J Neuroradiol 1998;19(5):894-896.
44. Lin RJ, Chen HF, Chang YC, Su JJ. Subacute combined degeneration caused by nitrous oxide intoxication: case reports. Acta Neurol Taiwan 2011;20 (2):129-137.
45. Shulman RM, Geraghty TJ, Tadros M. A case of unusual substance abuse causing myeloneuropathy. Spinal Cord 2007;45(4):314-317.
46. Quaghebeur G, Taylor WJ, Kingsley DPE, Fell JM, Reynolds AP, Milla PJ. MRI in children receiving total parenteral nutrition. Neuroradiology 1996;38(7): 680-683.